Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Harriet S. Walter, Sandrine Jayne, Simon A. Rule, Guillaume Cartron, Franck Morschhauser, Salvador Macip, Lionel Karlin, Ceri Jones, Charles Herbaux, Philippe Quittet, Nimish Shah, Claire V. Hutchinson, Christopher Fegan, Yingsi Yang, Siddhartha Mitra, Gilles Salles, Martin J. S. Dyer

Blood (2017) 129 (20): 2808–2810.

https://doi.org/10.1182/blood-2017-02-765115

Published: 2017

Includes: Supplemental data

Journal Articles

Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies

Gilles A. Salles, Franck Morschhauser, Bruce Cheson, MD, Simon A. Rule, MD, Christopher Fegan, Cartron Guillaume, Cara Nelson, Yingsi Yang, Siddhartha Mitra, Alexander Starodub, Martin J.S. Dyer

Blood (2016) 128 (22): 2961.

https://doi.org/10.1182/blood.V128.22.2961.2961

Published: 2016

Journal Articles

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Blood (2016) 128 (22): 2978.

https://doi.org/10.1182/blood.V128.22.2978.2978

Published: 2016

Journal Articles

Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia

Harriet S. Walter, Sandrine Jayne, Simon A. Rule, MD, Guillaume Cartron, MD PhD, Franck Morschhauser, Christopher Fegan, Yingsi Yang, Siddhartha Mitra, Martin J.S. Dyer, Gilles A. Salles

Blood (2016) 128 (22): 3233.

https://doi.org/10.1182/blood.V128.22.3233.3233

Published: 2016

Journal Articles

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

Blood (2016) 128 (22): 4403.

https://doi.org/10.1182/blood.V128.22.4403.4403

Published: 2016

Journal Articles

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

Michael Wang, MD, Peter Martin, MD, Tycel Phillips, MD, Andre Goy, MD, Izidore S Lossos, MD, Simon A. Rule, MD, Mehdi Hamadani, MD, Nilanjan Ghosh, MD PhD, Craig B. Reeder, MD, Evelyn Barnett, Marie-Laure Casadebaig Bravo, MSc, Stephen J. Schuster, MD

Blood (2016) 128 (22): 1786.

https://doi.org/10.1182/blood.V128.22.1786.1786

Published: 2016

Journal Articles

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Blood (2016) 127 (4): 411–419.

https://doi.org/10.1182/blood-2015-08-664086

Published: 2016

Includes: Supplemental data

Journal Articles

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Michael Wang, M.D., Simon A. Rule, MD, Peter Martin, MD, Andre Goy, MD, Rebecca Auer, MD, Brad S. Kahl, M.D., Wojciech Jurczak, Ranjana H. Advani, MD, Jorge Enrique E Romaguera, MD, Jesse McGreivy, MD, Fong Clow, ScD, Michelle Stevens-Brogan, Lori Kunkel, MD, Kristie A. Blum, MD

Blood (2012) 120 (21): 904.

https://doi.org/10.1182/blood.V120.21.904.904

Published: 2012

Journal Articles

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

Martin JS Dyer, MA, DPhil, FRCP, FRCPath, Andrew Grigg, MBBS, FRACP, FRCPA, Marcos González, Martin Dreyling, Simon A. Rule, MD, Guiyuan Lei, Elisabeth Wassner-Fritsch, Michael K. Wenger, MD, Paula Marlton, MBBS, FRACP, FRCPA

Blood (2012) 120 (21): 3686.

https://doi.org/10.1182/blood.V120.21.3686.3686

Published: 2012

Journal Articles

A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma

Bertrand Coiffier, MD, PhD, Evgenii Osmanov, MD, Xiaonan Hong, MD, Adriana Scheliga, MD, Jiri Mayer, MD, PhD, Fritz C Offner, MD, PhD, Simon A. Rule, MD, Adriana Teixeira, MD, Jan A Walewski, MD, PhD, DSc, Michael Crump, MD, FRCPC, Ofer Shpilberg, MD, MPH, Robert Hermann, MD, Sudha Parasuraman, MD, Eugene Zhu, PhD, Christopher Enny, BS, Panteli Theocharous, MSc, PhD, Helgi van de Velde, MD, PhD, Yusri Elsayed, MD, PhD, Pier Luigi Zinzani, MD, PhD

Blood (2010) 116 (21): 857.

https://doi.org/10.1182/blood.V116.21.857.857

Published: 2010

Journal Articles

Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)

Andrzej Hellmann, Simon A. Rule, Jan Walewski, Ofer Shpilberg, Huaibao Feng, Helgi van de Velde, Hamina Patel, Donna M Skee, Suzette Girgis, Vernon Louw

Blood (2010) 116 (21): 3983.

https://doi.org/10.1182/blood.V116.21.3983.3983

Published: 2010

NARROW

Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies

Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial

Long-Term Follow-up with GS-4059, a Selective Irreversible BTK Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia

Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial

Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000)

A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma

Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only